Literature DB >> 11255268

Mouse plasmacytoma: an experimental model of human multiple myeloma.

K Gadó1, S Silva, K Pálóczi, G Domján, A Falus.   

Abstract

BACKGROUND AND OBJECTIVES: There is no ideal animal model for human multiple myeloma (MM). All the models resemble the human disease in some respect, but none of them fulfils all the criteria of a perfect animal model. EVIDENCE AND INFORMATION SOURCES: The pristane oil (2,6,10,12-tetramethylpentadecane)-induced mouse plasmacytoma (MPC) model is the most widely used and accepted model and has provided the most data on plasmacytomagenesis so far. This model gives the opportunity to study the role of c-myc dysregulations, the mechanisms leading to cytogenetic changes involving Ig genes, the role of chronic inflammatory factors, the role of interleukin-6 (IL-6), insulin-like growth factor-I, prostaglandins, as well as signal transduction pathways in the neoplastic process. Therapeutic agents have been successfully tested. Although MPC growth is usually restricted to the peritoneal environment, intraperitoneal injection of MPC cell suspensions can reproduce the disseminated characteristics of the human disease in recipients. The IL-6 transgene and knockout models are important tools for clarifying the role of IL-6 in the pathogenesis of MM. Transgenic mice and retroviral gene transfer facilitate the study of oncogenes in neoplastic transformation. Spontaneous development of plasmacytomas in C57BL/ KaLwRij aging mice has several advantages, mainly because the disseminated growth, the typical bone lesions and renal involvement resemble, in part, the human disease. Furthermore, this model has already proved useful in studies on the effect of bisphosphonate in the treatment of bone disease in MM. The severe combined immunodeficiency (SCID) mouse model is also very attractive. A disseminated-like disease can be reproduced in this model. Multiple osteolytic bone lesions and bone marrow involvement are generated, and conventional drugs applied in the treatment of human multiple myeloma have proven to be effective. Nevertheless, the immune system of SCID mice basically differs from that of a MM patient. PERSPECTIVES: Taken together, all these models have contributed to our understanding of MM, but demonstrate the opportuness of developing a more appropriate model of the human disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11255268

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  20 in total

1.  Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.

Authors:  Lai Sum Leoh; Yoon Kyung Kim; Pierre V Candelaria; Otoniel Martínez-Maza; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  J Immunol       Date:  2018-04-13       Impact factor: 5.422

2.  An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.

Authors:  Tracy R Daniels; Elizabeth Ortiz-Sánchez; Rosendo Luria-Pérez; Rafaela Quintero; Gustavo Helguera; Benjamin Bonavida; Otoniel Martínez-Maza; Manuel L Penichet
Journal:  J Immunother       Date:  2011 Jul-Aug       Impact factor: 4.456

3.  Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor.

Authors:  Patrick P Ng; Gustavo Helguera; Tracy R Daniels; Simon Z Lomas; Jose A Rodriguez; Gary Schiller; Benjamin Bonavida; Sherie L Morrison; Manuel L Penichet
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

4.  Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.

Authors:  Apollina Goel; Angela Dispenzieri; Susan M Geyer; Suzanne Greiner; Kah-Whye Peng; Stephen J Russell
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

5.  Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.

Authors:  E E Fink; S Mannava; A Bagati; A Bianchi-Smiraglia; J R Nair; K Moparthy; B C Lipchick; M Drokov; A Utley; J Ross; L P Mendeleeva; V G Savchenko; K P Lee; M A Nikiforov
Journal:  Leukemia       Date:  2015-07-24       Impact factor: 11.528

6.  IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1.

Authors:  Yijiang Shi; Patrick J Frost; Bao Q Hoang; Angelica Benavides; Sanjai Sharma; Joseph F Gera; Alan K Lichtenstein
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 7.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Expression profiling revealed keratins and interleukins as potential biomarkers in squamous cell carcinoma of horn in Indian bullocks (Bos indicus).

Authors:  Ketankumar Panchal; Prakash Koringa; Pritesh Sabara; Dhruv Bhatia; Subhash Jakhesara; Chaitanya Joshi
Journal:  3 Biotech       Date:  2020-02-05       Impact factor: 2.406

9.  Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment.

Authors:  Rosemary A Fryer; Timothy J Graham; Emma M Smith; Simon Walker-Samuel; Gareth J Morgan; Simon P Robinson; Faith E Davies
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

10.  Acid-mediated reactions under microfluidic conditions: a new strategy for practical synthesis of biofunctional natural products.

Authors:  Katsunori Tanaka; Koichi Fukase
Journal:  Beilstein J Org Chem       Date:  2009-08-20       Impact factor: 2.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.